فلوسي‌توسين

فلوسي‌توسين

البيانات السريرية
فئة السلامة أثناء الحمل	AU: B3
مسارات الدواء	Oral, intravenous
رمز ATC	D01AE21 (WHO) J02AX01
الحالة القانونية
الحالة القانونية	UK: POM (Prescription only) US: ℞-only
بيانات الحركية الدوائية
التوافر الحيوي	75 to 90% (oral)
ارتباط الپروتين	2.9 to 4%
الأيض	Minimal, in the GI tract
Elimination half-life	2.4 to 4.8 hours
الإخراج	Renal (90%)
المعرفات
IUPAC name 4-amino-5-fluoro-1,2-dihydropyrimidin-2-one
رقم CAS	2022-85-7
PubChem CID	3366
DrugBank	APRD00299
CompTox Dashboard (EPA)	DTXSID3023059
ECHA InfoCard	100.016.336
Chemical and physical data
التركيب	C4H4FN3O
الكتلة المولية	129.093 g/mol

فلوسي‌توسين Flucytosine أو 5-فلوروسيتوسين، هو fluorinated pyrimidine مشتق تخليقي مضاد للفطريات , و له علاقة من الناحية التركيبية ب cytostatic fluorouracil و ب floxuridine. وهو متوافر بصورة عن طريق الفم, وبصورة دواء للحقن في بعض البلدان. وإسمه الشائع Ancobon, يباع في كبسولات 250 مج و 500 مج. أما الصورة التى تعطى عن طريق الحقن فتخفف في 250 ملي من محلول الملح لكى تحتوى على 2.5 جم كليا ( 10 مج/ملي). والمحلول فيزيائيا غير متوافق مع الأدوية الأخرى مثل amphotericin B

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 الفارماكولوجي

 نظرية العمل

Two major mechanisms of action have been elucidated:

• One is that the drug is intrafungally converted into the cytostatic flourouracil that undergoes further steps of activation and finally interacts as 5-fluorouridinetriphosphate with RNA biosynthesis and disturbs the building of certain essential proteins.
• The other mechanism is the conversion into 5-flourodeoxyuridinemonophosphate which inhibits fungal DNA synthesis.

 Spectrum of susceptible fungi and resistance

Flucytosine is active in vitro as well as in vivo against some strains of Candida and Cryptococcus. Limited studies demonstrate that flucytosine may be of value against infections with Sporothrix, Aspergillus, Cladosporium, Exophila, and Phialophora. Resistance is quite commonly seen as well in treatment naive patients and under current treatment with flucytosine. In different strains of Candida resistance has been noted to occur in 1 to 50% of all specimens obtained from patients.

 بيانات الحراك الدوائى

Flucytosine is well absorbed (75 to 90%) from the gastrointestinal tract. Intake with meals slows the resorption, but does not decrease the amount resorbed. Following an oral dose of 2 grams peak serum levels are reached after approximately 6 hours. The time to peak level decreases with continued therapy. After 4 days peak levels are measured after 2 hours. The drug is eliminated renally. In normal patients flucytosine has reportedly a half-life of 2.5 to 6 hours. In patients with impaired renal function higher serum levels are seen and the drug tends to cumulate in these patients. The drug is mainly excreted unchanged in the urine (90% of an oral dose) and only traces are metabolized and excreted in the feces. Therapeutic serum levels range from 25 to 100mcg/ml. Serum levels in excess of 100mcg are associated with a higher incidence of side-effects. Periodic measurements of serum levels are recommended for all patients and are a must in patients with renal damage.

 الجرعات الزائدة في الإنسان

Symptoms and their severities are unknown, because flucytosine is used under close medical supervision, but expected to be an excess of the usually encountered side effects on the bone marrow, gastrointestinal tract, liver and kidney function. Vigorous hydration and hemodialysis may be helpful to remove the drug from the body. Hemodialysis is particular useful in patients with impaired renal function.

 القابلية للسرطنة لدى الإنسان

It is not known if flucytosine is a human carcinogen. The issue has been raised because traces of 5-fluorouracil, which is a known carcinogen, are found in the colon resulting from the metabolization of flucytosine.

 دواعي الإستعمال

Oral flucytosine is indicated for the treatment of serious infections caused by susceptible strains of Candida or Cryptococcus neoformans. It can also be used for the treatment of chronomycosis (chromoblastomycosis), if susceptible strains cause the infection. Flucytosine must not be used as a sole agent in life-threatening fungal infections due to relatively weak antifungal effects and fast development of resistance, but rather in combination with amphotericin B and/or azole antifungals such as fluconazole or itraconazole. Minor infections such as candidal cystitis may be treated with flucytosine alone. In some countries, treatment with slow intravenous infusions for no more than a week is also a therapeutic option, particular if the disease is life-threatening.

 مضادلت الإستعمال ومحاذير

• All patients receiving flucytosine should be under strict medical supervision.
• Hematological, renal and liver function studies should be done frequently during therapy (initially daily, twice a week for the rest of treatment).
• Patients with preexisting bone marrow depression and liver impairment should be treated with caution.
• Concomitant treatment with brivudine is an absolute contraindication.
• Patients treated with drugs compromising bone marrow function (e.g. cytostatics) should be treated carefully. Blood cell counts should be taken very frequently.
• Patients with renal disease should receive flucytosine cautiously and in reduced doses. Guidelines for proper dosing exist. Serum level determinations are mandatory in these patients.
• Hypersensitivity to flucytosine is an absolute contraindication.

 مجموعات مرضية خاصة

 الحمل و الإرضاع

In animal models (rats), flucytosine has been found to be teratogenic. Sufficient human data does not exist. Pregnant women should be given flucytosine only if the potential benefits exceed the potential harm to the fetus.

It is not known if flucytosine is distributed in human breast milk. Given the potential risk to the child, the patient should not breastfeed during treatment with flucytosine.

 الأطفال

The efficacy and safety in patients under 18 years of age has not been determined.

 الآثار الجانبية

• Antiproliferative actions on bone marrow and GI tissue: Due to the drug's preference to affect rapidly proliferating tissues, bone marrow depression (anemia, leukopenia, pancytopenia, or even rarely agranulocytosis) may occur. Aplastic anemia has also been seen. Bone marrow toxicity can be irreversible and may cause death, particular in immunocompromised patients. GI toxicity may be severe or rarely fatal and consists of anorexia, abdominal bloating, abdominal pain, diarrhea, dry mouth, duodenal ulcer, GI hemorrhage, nausea, vomiting, and ulcerative colitis.

• Liver function: Elevations of liver enzymes and bilirubin, hepatic dysfunction, jaundice and, in one patient, liver necrosis have all been seen. Some fatal cases have been reported, however the majority of cases was reversible.

• Renal function: Increased BUN and serum creatinine have been noted. Crystalluria (formation of crystals and excretion in the urine) and acute renal failure have also been seen.

• Adverse central nervous system effects are frequent and include confusion, hallucinations, psychosis, ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, vertigo and sedation.

• Skin reactions: Rash, pruritus, and photosensitivity have all been noticed. Toxic epidermal necrolysis (Lyell's syndrome) may also be encountered and may be life-threatening.

• Anaphylaxis: Sometimes cases of anaphylaxis consisting of diffuse erythema, pruritus, conjunctival injection, fever, abdominal pain, edema, hypotension and bronchospastic reactions are observed.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 التداخلات الدوائية

For details see Contraindications and Cautions. Flucytosine may increase the toxicity of amphotericin B and vice versa, although the combination may be life-saving and should be used whenever indicated (e.g., cryptococcal meningitis). The cytostatic cytarabine inhibits the antimycotic activity of flucytosine.

 الجرعات

The recommended daily dose is 50 to 150mg per kilogram of bodyweight orally, divided in 4 equal doses every 6 hours. If problems exist to swallow a complete single dose, the dose may be given in several partial amounts over 15 minutes. The dose for intravenous infusions is 50mg per kg infused over 20 to 40 minutes every 6 hours. The duration of treatment depends on the clinical situation, but generally does not exceed 7 days.

 الإستعمال في مرضي غير محددين

Serious fungal infections often occur in immunocompromised (e.g. HIV-infected) patients. These patients benefit from combination therapy including flucytosine, but the incidence of side-effects of a combination therapy, particular with amphotericin B, may be higher than in immunocompetent patients.

 الإستعمال البيطري

In some countries, such as Switzerland, flucytosine has been licensed to treat cats, dogs and birds (in most cases together with amphotericin B) for the same indications as in humans.

 المراجع

• AHFS Database online
• ClinPharm Wirkstoffliste (Switzerland, German information)